GSK1278863

Phase 3Small molecule

GSK

GSK1278863 is one of 70 small molecule programs targeting Anemia. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

AnemiaActive, not recruiting

Thoracic Aortic AneurysmActive, not recruiting

Chronic Kidney DiseaseActive, not recruiting

AnemiaPhase 3

Active, not recruiting

Thoracic Aortic AneurysmPhase 2

Active, not recruiting

Chronic Kidney DiseasePhase 2

Active, not recruiting

Competition

Competitive Landscape

540 competitors in Chronic Kidney Disease

#DrugCompanyPhaseTrials

GSK1278863

GSK

Phase 3

8 2

Aranesp

Amgen

Preclinical

40 3

Epogen

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Preclinical

16 4

Uloric

Takeda

Preclinical

3 5

Glucotrol

Pfizer

Preclinical

1 6

Flomax

Epoetin Beta

5 8

Verquvo

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Preclinical

1 9

PROCRIT

WWim Janssens

Preclinical

1 10

Januvia

ZZydus Therapeutics Inc.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Chronic Kidney Disease8 trials

Evaluation of Dose Response Relationship, Safety and Efficacy of GSK1278863 in Hemodialysis-dependent Subjects With Chronic Kidney Disease Associated Anemia

Completed· GSK logo

GSK·Phase 2·NCT01977482·216 enrolled

Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Three-times Weekly Dosing of GSK1278863 in Hemodialysis-dependent Subjects With Anemia Associated With Chronic Kidney Disease Who Are Switched From a Stable Dose of an Erythropoiesis-stimulating Agent

Completed· GSK logo

GSK·Phase 2·NCT02689206·103 enrolled

Study to Evaluate the Safety and Efficacy of GSK1278863 in Recombinant Human Erythropoietin (rhEPO) Hyporesponsive Hemodialysis-dependent Chronic Kidney Disease Subjects With Anemia

Terminated· GSK logo

GSK·Phase 2·NCT02075463·15 enrolled

Show 5 more trials

Efficacy and Safety Study of GSK1278863 in Japanese Hemodialysis Subjects With Anemia Associated With Chronic Kidney Disease Who Are Not Taking Erythropoiesis Stimulating Agents

Completed· GSK logo

GSK·Phase 3·NCT02829320·28 enrolled

4 Week Correction Study in Subjects With Anemia Associated With Chronic Kidney Disease Who Are Not Undergoing Dialysis

Completed· GSK logo

GSK·Phase 2·NCT01587898·72 enrolled

4 Week Switch Study in Hemodialysis-dependent Subjects With Anemia Associated With Chronic Kidney Disease

Completed· GSK logo

GSK·Phase 2·NCT01587924·80 enrolled

A Study to Evaluate Safety and Efficacy of GSK1278863 in Non-Dialysis Dependent (NDD) Subjects With Anemia Associated With Chronic Kidney Diseases (CKD)

Completed· GSK logo

GSK·Phase 2·NCT01977573·252 enrolled

Study to Evaluate the Safety, Efficacy and Pharmacokinetics of GSK1278863 in Japanese Hemodialysis-Dependent Subjects With Anemia Associated With Chronic Kidney Disease

Completed· GSK logo

GSK·Phase 2·NCT02019719·97 enrolled

Tics2 trials

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of Single and Repeated Doses of Topical GSK1278863

Completed· GSK logo

GSK·Phase 1·NCT01831804·65 enrolled

Study to Assess the Pharmacokinetics of GSK1278863A Coadministered With a High Fat Meal or an Inhibitor of CYP2C8 (Gemfibrozil)

Completed· GSK logo

GSK·Phase 1·NCT01376232·23 enrolled

ART1 trial

Effects of GSK1278863A on Pulmonary Artery Pressure in Healthy Volunteers

Completed· GSK logo

GSK·Phase 1·NCT01673555·49 enrolled

Thoracic Aortic Aneurysm1 trial

Study of GSK1278863 to Reduce Ischemic Events in Patients Undergoing Thoracic Aortic Aneurysm Repair

Completed· GSK logo

GSK·Phase 2·NCT01920594·57 enrolled

Exercise1 trial

GSK1278863 Effects on Eccentric Exercise-Induced Muscle Damage

Completed· GSK logo

GSK·Phase 1·NCT02231190·26 enrolled

6 more indications

End-Stage Renal Disease1 trial

Study to Assess the Pharmacokinetics of GSK1278863 in Subjects With End Stage Renal Disease Undergoing Peritoneal Dialysis

Completed· GSK logo

GSK·Phase 1·NCT02243306·8 enrolled

Interaction1 trial

Drug-drug Interaction Study of GSK1278863 With Pioglitazone, Rosuvastatin and Trimethoprim in Healthy Adult Volunteers

Completed· GSK logo

GSK·Phase 1·NCT02371603·70 enrolled

Renal Impairment1 trial

Assessment of the Pharmacokinetics of GSK1278863 and Metabolites in Normal Subjects and Subjects With Renal Impairment

Terminated· GSK logo

GSK·Phase 1·NCT01406340·22 enrolled

Single Dose1 trial

Single Dose, Pharmacokinetic, Safety, Tolerability and QTc Study of GSK1278863 in Healthy Volunteers

Completed· GSK logo

GSK·Phase 1·NCT02293148·61 enrolled

Anemia1 trial

Phase III Study of GSK1278863 in Japanese Non-dialysis (ND) and Peritoneal Dialysis (PD) Subjects With Renal Anemia

Completed· GSK logo

GSK·Phase 3·NCT02791763·355 enrolled

Unspecified1 trial

3 Month PHI PAD PoM Study

Completed· GSK logo

GSK·Phase 2·NCT02135848·46 enrolled

Sources

References

[1]
ClinicalTrials.gov — 19 trial records for GSK1278863. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — GSK1278863 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for GSK1278863. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — GSK company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: GSK

GSK1278863

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Chronic Kidney Disease8 trials

Tics2 trials

ART1 trial

Thoracic Aortic Aneurysm1 trial

Exercise1 trial

End-Stage Renal Disease1 trial

Interaction1 trial

Renal Impairment1 trial

Single Dose1 trial

Anemia1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News